About A public-private partnership that supports the discovery of new medicines through open access research. About SGC Partners Research Laboratories SGC-Toronto SGC-UNC SGC-Frankfurt SGC-Karolinska SGC-Neuro Governance Collaborators Open Science Equity, Diversity and Inclusion Impact Science and Resources Proteins Structure Gallery Expression Vectors Plasmids Constructs Production Protocols ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees ChemBioPort Chemical Probes Program CHEMICAL PROBES Donated chemical probes Chemical Handles Human Kinase Chemical Probe Program ANTIBODIES TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM Open Lab Notebooks Open Chemistry Network PUBLICATIONS People Global Aled Edwards, CEO Susan McCormick, CFO Max Morgan, General Counsel and Public Policy Director SGC Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Takis Prinos Matthieu Schapira Levon Halabelian Rachel Harding SGC UNC Tim Willson Alison Axtman David Drewry Peter J. Brown Rafael M. Couñago SGC UCL Mat Todd SGC Karolinska Michael Sundström Opher Gileadi SGC Frankfurt Stefan Knapp Susanne Müller-Knapp Thomas Hanke Vladimir Rogov Krishnal Saxena Andreas Joerger Václav Němec Andreas Krämer Sandra Röhm SGC Neuro Edward Fon Thomas Durcan Jean-François Trempe Ziv Gan-Or Peter McPherson Carl Laflamme Roxanne Lariviere News & Outreach News & Events News from SGC Press Releases Events Blog Tweets by thesgconline Careers
A public-private partnership that supports the discovery of new medicines through open access research.
IOX2 A selective Inhibitor of the Hypoxia Inducible Factor (HIF) Prolyl-HydroxylasesThis probe is available from Cayman Chemical, Sigma and Tocris For any inquiries please contact proberequests@thesgc.org.group newOverviewBiology of the hypoxia inducible factor (HIF) prolyl-hydroxylases Levels of the Hypoxia Inducible Factor (HIF), a master regulator of the cellular-response to hypoxia, are regulated by the post-translational modification of prolyl-residues in oxygen-dependent degradation domains in the HIFα subunit. HIFα prolyl-hydroxylation signals for its degradation by the proteasome. The requirement of the HIF prolyl-hydroxylases (PHD or EGLN enzymes) for dioxygen as a co-substrate enables them to act as the hypoxia-sensing component of the HIF system. PHDs are members of the 2-oxoglutarate (2OG-dependent) oxygenase superfamily. Inhibition of the PHDs reduces HIFα prolyl-hydroxylation thereby elevating HIF levels and artificially inducing the hypoxic response. Because HIF-target genes include those encoding for biomedically important proteins such as erythropoietin (EPO) and vascular endothelial growth factor (VEGF), PHD inhibition is of considerable medical interest. IOX2: A chemical probe for HIF prolyl-hydroxylases IOX2, a chemical probe for HIF prolyl-hydroxylases is the result of collaborations with the University of Sevilla, Genome Institute of Singapore, University of Sheffield, University of Oxford, BioNanotechnology Research Center KRIBB and the SGC [1]. Potency Against Target Family IOX2 displayed an AlphaScreen IC50 of 22nM for inhibition of PHD2 Selectivity Beyond Target Family IOX2 was found to be inactive against a panel of 55 receptors and ion channels (CEREP panel) at 10µM. Co-crystal structure The co-crystal structure of IOX2 with PHD2 has NOT been solved, however, there is a crystal structure with a close analogue (pdb id: 4BQW). This analogue has a methyl rather than benzyl group on the isoquinoline nitrogen. Please click on the 'Co-Crystal structures' tab above for more details. Cellular Activity IOX2 showed selective inhibition (by Western blot) of PHD catalysed HIF-1α prolyl-hydroxylation in a variety of human cell lines including renal carcinoma (RCC4) cell line lacking VHL, embryonic kidney (293T), bone osteosarcoma (U2OS) and RCC4 reexpressing VHL (RCC4/VHL) cells. Properties (1-benzyl-4-hydroxy-2-oxo-1, 2-dihydroquinoline-3-carbonyl)glycine For SDF click here Physical and chemical properties Molecular weight 352.35 Molecular formula C19H16N2O5 IUPAC name (1-benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine logP -3.99 PSA No. of chiral centres 0 No. of rotatable bonds 5 No. of hydrogen bond acceptors 7 No. of hydrogen bond donors 3 Storage Store at -20°C Dissolution Soluble to 100 uM in DMSO An inactive, negative control for IOX2 has not yet been identified Selectivity ProfilePotency against Target IOX2 displayed an AlphaScreen IC50 of 22nM for inhibition of PHD2; values for each data point are averages ± standard deviation (n≥3). Selectivity against Histone Demethylases IOX2 was profiled against a panel of human histone Nε-methyl lysine demethylase 2OG-oxygenases in an AlphaScreen assay to determine selectivity. Selectivity Beyond Target Family IOX2 was found to be inactive against a panel of 55 receptors and ion channels (CEREP panel) at 10µM. Click to enlarge Cell-based Assay DataEngagement of IOX2 in an in vitro cell assay Efficacy of IOX2 in a human renal carcinoma (RCC4) cell line lacking VHL (required for the degradation of hydroxylated HIF-α) was established, using antibodies selective for hydroxylated form(s) of a peptide corresponding to the HIF-1α C-terminal oxygen-dependent degradation domain to probe for PHD catalysed inhibition of HIF prolyl-hydroxylation in comparison to FIH catalysed asparaginyl-hydroxylation. IOX2 was further tested in VHL-competent cell lines, including human embryonic kidney (293T), human bone osteosarcoma (U2OS) and RCC4 reexpressing VHL (RCC4/VHL) cells, where increased HIF-1α levels were used as an indicator for PHD inhibition. IOX2 effectively increased HIF-1α levels in all tested VHL-competent cell lines showing that the inhibitory effects are independent of cell type. These results establish that IOX2 is a potent and selective cellular PHD inhibitor. Selective inhibition of IOX2 in human cell lines. Selectivity of the tested inhibitors for HIF-1α prolyl- over asparaginyl- hydroxylation in RCC4 after 6h of treatment. Upregulation of HIF-1α by inhibitors in various cell types (after 6h of treatment): HEK293T, U2OS and RCC4 stably-transfected with C-HA-tagged wildtype VHL. Co-crystal structuresA co-crystal structure of PHD2’s catalytic domain with a methyl group on the isoquinoline nitrogen, compound 1, (rather than benzyl group in IOX2) group has been solved (pdb id 4BQW). Compound 1 The bicyclic heteroaromatic ring of IOX2 is sandwiched between the hydrophobic side chains of Tyr310, Met299 and Trp389. IOX2 coordinates Mn(II) (substituting for Fe(II)) in a bidentate fashion with the side chain amide-carbonyl and phenolic oxygen. The side chain carboxylate of IOX2 is positioned to hydrogen bond with Arg383 and Tyr329. The Tyr303 phenol is positioned to hydrogen bond to the isoquinoline-2-OH. The aromatic rings of IOX2 project through the active site opening and likely make a steric clash with the hydroxylated HIF-1α. References Selective Small Molecule Probes for the Hypoxia Inducible Factor (HIF) Prolyl Hydroxylases, Rasheduzzaman Chowdhury, José Ignacio Candela-Lena, Mun Chiang Chan, David Jeremy Greenald, Kar Kheng Yeoh, Ya-Min Tian, Michael A. McDonough, Anthony Tumber, Nathan R. Rose, Ana Conejo-Garcia, Marina Demetriades, Mathavan Sinnakaruppan, Akane Kawamura, Myung Kyu Lee, Freek van Eeden, Christopher W. Pugh, Peter J. Ratcliffe, Christopher J. Schofield. ACS Chemical Biology 2013; 8: 1488-1496. Plant Growth Regulator Daminozide Is a Selective Inhibitor of Human KDM2/7 Histone Demethylases, Rose, N. R., Woon, E. C., Tumber, A., Walport, L. J., Chowdhury, R., Li, X. S., King, O. N., Lejeune, C., Ng, S. S., Krojer, T., Chan, M. C., Rydzik, A. M., Hopkinson, R. J., Che, K. H., Daniel, M., Strain-Damerell, C., Gileadi, C., Kochan, G., Leung, I. K., Dunford, J., Yeoh, K. K., Ratcliffe, P. J., Burgess-Brown, N., von Delft, F., Muller, S., Marsden, B., Brennan, P. E., McDonough, M. A., Oppermann, U., Klose, R. J., Schofield, C. J., and Kawamura, A., J. Med. Chem. 2012, 55, 6639−6643 Monoclonal antibody-based screening assay for factor inhibiting hypoxia-inducible factor inhibitors, SH Lee, M Jeong Hee, Ah C. Eun, SE Ryu, and L Myung Kyu. Journal of Biomolecular Screening 2008; 13:494−503 Development of homogeneous luminescence assays for histone demethylase catalysis and binding, Kawamura, A.; Tumber, A.; Rose, N. R.; King, O. N.; Daniel, M.; Oppermann, U.; Heightman, T. D.; Schofield, C. J. Anal Biochem, 2010, 404, 86-93